Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. I'm Paul Choi, the Mid-cap Biotechnology Analyst at Goldman Sachs, and we'll continue with our next session here, which is with Phathom Pharmaceuticals. From the Management side, we are very happy to have Terrie Curran, the CEO. Also on the line with us is Azmi Nabulsi, who is the COO.
As with prior sessions, what we'll do is let Terrie kick it off with some opening remarks and an introduction to the company. After that, we'll go into the Q&A portion of the session. (Operator Instructions)
And that -- with that, I'll turn it over to Terrie for an overview of Phathom. Terrie?
Thank you, Paul, and thank you for inviting us today, and hello, everybody. As Paul said, my name is Terrie Curran, I'm the CEO of Phathom. Phathom is a clinical stage company, our lead asset is vonoprazan, and vonoprazan is a potassium competitive acid blocker. The company was formed very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
